slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Presented By Eric Winer at 2014 ASCO Annual Meeting PowerPoint Presentation
Download Presentation
Presented By Eric Winer at 2014 ASCO Annual Meeting

Loading in 2 Seconds...

play fullscreen
1 / 30

Presented By Eric Winer at 2014 ASCO Annual Meeting - PowerPoint PPT Presentation


  • 121 Views
  • Uploaded on

Breast Plenary Abstracts<br />How Do These Studies Impact Clinical Practice Today and in the Years Ahead?<br />. Presented By Eric Winer at 2014 ASCO Annual Meeting.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Presented By Eric Winer at 2014 ASCO Annual Meeting' - sabin


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
Breast Plenary Abstracts<br />How Do These Studies Impact Clinical Practice Today and in the Years Ahead?<br />

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide2

First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their combination (L + T) in the adjuvant treatment of HER2-positive <br />early breast cancer (EBC)

Presented By Eric Winer at 2014 ASCO Annual Meeting

n9831 b 31 disease free survival
N9831/B-31 Disease-Free Survival

Presented By Eric Winer at 2014 ASCO Annual Meeting

pathologic response in neo altto
Pathologic Response in Neo-ALTTO

Presented By Eric Winer at 2014 ASCO Annual Meeting

calgb 40601 th vs tl vs thl
CALGB 40601 (TH vs TL vs THL)

Presented By Eric Winer at 2014 ASCO Annual Meeting

adjuvant lapatinib altto schema
Adjuvant Lapatinib (ALTTO) Schema

Presented By Eric Winer at 2014 ASCO Annual Meeting

disease free survival dfs analysis
Disease Free Survival (DFS) Analysis

Presented By Eric Winer at 2014 ASCO Annual Meeting

disease free survival by hormone receptor status
Disease Free Survival By Hormone Receptor Status

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide 9
Slide 9

Presented By Eric Winer at 2014 ASCO Annual Meeting

overall survival os analysis
Overall Survival (OS) Analysis

Presented By Eric Winer at 2014 ASCO Annual Meeting

main differences in aes by treatment arm
Main Differences In AEs By Treatment Arm

Presented By Eric Winer at 2014 ASCO Annual Meeting

thoughts about altto
Thoughts About ALTTO

Presented By Eric Winer at 2014 ASCO Annual Meeting

further implications for research and practice
Further Implications for Research and Practice

Presented By Eric Winer at 2014 ASCO Annual Meeting

why improvement in pathologic complete response may not lead to change in dfs
Why Improvement in Pathologic Complete Response May Not Lead to Change in DFS

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide15

Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function Suppression<br /> vs Tamoxifen plus Ovarian Function Suppression<br />in Premenopausal Women <br />with Hormone Receptor Positive Early Breast Cancer: <br />Joint Analysis of IBCSG TEXT and SOFT

Presented By Eric Winer at 2014 ASCO Annual Meeting

study schemas total n 4690
Study Schemas (Total N=4690)

Presented By Eric Winer at 2014 ASCO Annual Meeting

improved dfs with exemestane ofs vs tamoxifen ofs
Improved DFS with Exemestane + OFS vs Tamoxifen + OFS

Presented By Eric Winer at 2014 ASCO Annual Meeting

sites of first failure
Sites of First Failure

Presented By Eric Winer at 2014 ASCO Annual Meeting

overall survival at 5 years
Overall Survival at 5 Years

Presented By Eric Winer at 2014 ASCO Annual Meeting

women who did not receive chemotherapy
Women Who Did Not Receive Chemotherapy

Presented By Eric Winer at 2014 ASCO Annual Meeting

selected adverse events
Selected Adverse Events

Presented By Eric Winer at 2014 ASCO Annual Meeting

adverse events and qol
Adverse Events and QOL

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide 23
Slide 23

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide24
Does Ovarian Suppression Add To Tamoxifen In Premenopasual Women?<br />Findings FromThe LHRH Meta-Analysis<br />

Presented By Eric Winer at 2014 ASCO Annual Meeting

slide 25
Slide 25

Presented By Eric Winer at 2014 ASCO Annual Meeting

primary end point disease free survival br no significant difference between tam and ana
Primary End Point: Disease-Free Survival<br />No Significant Difference Between TAM and ANA

Presented By Eric Winer at 2014 ASCO Annual Meeting

is os ai the new standard of care
Is OS + AI The New Standard of Care?

Presented By Eric Winer at 2014 ASCO Annual Meeting

what to consider when you go home 1
What To Consider When You Go Home (1)

Presented By Eric Winer at 2014 ASCO Annual Meeting

what to consider when you go home 2
What To Consider When You Go Home (2)

Presented By Eric Winer at 2014 ASCO Annual Meeting

thank you
Thank you

Presented By Eric Winer at 2014 ASCO Annual Meeting